LumaVida is, at its core, a women’s-health-impact business: it exists to expand access to high-quality obstetric, gynaecological, fertility and preventive care in a country where women’s-health specialists are scarce and unevenly distributed. Its ESG framework is substantive, not cosmetic, and aligns directly with the mandates of impact-health and development-finance investors.

Social and health impact

• Access to women’s health — specialist obstetric, gynaecological and preventive care in provinces where women’s-health specialists are scarce.
• Early detection & screening — cervical, breast-adjacent and other cancer screening, and diabetes-in-pregnancy management, catch disease early when it is treatable.
• Maternal health — high-quality antenatal, high-risk-pregnancy and postpartum care improves maternal and newborn outcomes.
• Skills & jobs — over 200 skilled healthcare jobs, and support for growing the scarce women’s-health specialist workforce.

Alignment with development priorities

LumaVida’s impact maps directly onto recognised health and development priorities, which is what makes the plan financeable to impact-health and development-finance capital.

Governance and environment

Clinical governance, credentialing, outcome audit, patient safety and infection control, is the foundation of the Group’s ESG framework, alongside B-BBEE participation, data-privacy compliance for the App and electronic medical records (a particular responsibility given sensitive women’s-health data), and environmentally efficient clinic design. The Group will report against health-outcome and access metrics from the outset, both because impact investors require it and because that data is a commercial and reputational asset.